1. Scrip
  2. >>R&D
  3. >>Clinical Trials

CymaBay Focused On PBC With Seladelpar, Wants Partner For NASH

 
• By Joseph Haas

With an FDA clinical hold lifted, CymaBay plans to initiate a new Phase III in primary biliary cholangitis early in 2021. It also hopes to partner the drug in NASH with a company developing a metabolic drug for the disease.

scientists doing lab research on digital screen
CymaBay's PBC candidate shows fibrosis, inflammation, liver marker benefits

Positive findings from CymaBay Therapeutics, Inc.’s halted Phase III trial of seladelpar in primary biliary cholangitis, presented at the American Association for Study of Liver Disease, are helping get the PPAR delta agonist back on track. CEO Sujal Shah told Scrip that while PBC remains the top priority for his company, it also hopes to position seladelpar as part of combination therapy in non-alcoholic steatohepatitis with a drug that can provide metabolic benefit to patients.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

DIA Korea: Medical Turmoil, Global Factors Blunt Korea’s Trial Edge

 
• By Jung Won Shin

DIA Korea hears how multiple domestic and global factors are affecting the environment for clinical trials in South Korea, and what actions may be taken to address this.

Moderna Punts On US Vaccine Policy Changes, Will Focus More On Cancer

 
• By Joseph Haas

On its Q1 earnings call, Moderna avoided criticizing policy changes affecting vaccines but de-emphasized its flu/COVID-19 vaccine for under-50 and prioritized cancer programs.

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

More from R&D